KNSA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.34
Percentage change -1.51	%

Peers: AMGN REGN BIIB VRTX GILD INCY BMRN NBIX EXEL SAGE

| Held by: VTI IWM VB VBK IWO VTWO DFAS VHT DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.61	Insider Own	44.72%	Shs Outstand	41.88M	Perf Week	4.18%
Market Cap	1.61B	Forward P/E	17.93	EPS next Y	1.24	Insider Trans	-0.78%	Shs Float	40.16M	Perf Month	12.49%
Income	-43.19M	PEG	-	EPS next Q	0.14	Inst Own	54.48%	Short Float	7.47%	Perf Quarter	3.94%
Sales	423.24M	P/S	3.80	EPS this Y	212.29%	Inst Trans	-7.13%	Short Ratio	5.13	Perf Half Y	-8.16%
Book/sh	6.05	P/B	3.67	EPS next Y	83.39%	ROA	-7.80%	Short Interest	3.00M	Perf Year	8.95%
Cash/sh	3.35	P/C	6.61	EPS next 5Y	-	ROE	-9.85%	52W Range	16.56 - 28.15	Perf YTD	12.03%
Dividend Est.	-	P/FCF	63.35	EPS past 5Y	27.38%	ROI	-9.68%	52W High	-21.28%	Beta	0.30
Dividend TTM	-	Quick Ratio	3.04	Sales past 5Y	140.87%	Gross Margin	55.19%	52W Low	33.82%	ATR (14)	0.90
Dividend Ex-Date	-	Current Ratio	3.30	EPS Y/Y TTM	-403.56%	Oper. Margin	-10.78%	RSI (14)	64.22	Volatility	4.81% 4.11%
Employees	315	Debt/Eq	0.02	Sales Y/Y TTM	56.60%	Profit Margin	-10.21%	Recom	1.00	Target Price	35.86
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-135.39%	Payout	0.00%	Rel Volume	0.85	Prev Close	22.50
Sales Surprise	-0.71%	EPS Surprise	-597.93%	Sales Q/Q	46.93%	Earnings	Feb 25 BMO	Avg Volume	585.18K	Price	22.16
SMA20	7.74%	SMA50	11.03%	SMA200	0.01%	Trades		Volume	500,058	Change	-1.51%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Citigroup	Buy	$40
Sep-13-24	Initiated	Jefferies	Buy	$40
May-03-24	Initiated	Wells Fargo	Overweight	$34
Jun-29-20	Reiterated	BofA Securities	Buy	$25 → $40
Apr-01-20	Initiated	BofA/Merrill	Buy	$25
Mar-11-19	Initiated	Barclays	Overweight	$26
Dec-12-18	Reiterated	Wedbush	Outperform	$31 → $33
Jun-19-18	Initiated	JMP Securities	Mkt Outperform	$33

Mar-06-25 08:23AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best UK Growth Stock to Buy Now? (Insider Monkey)
Mar-04-25 12:20PM	Surging Earnings Estimates Signal Upside for Kiniksa Pharmaceuticals (KNSA) Stock (Zacks)
03:05AM	Kiniksa Pharmaceuticals (KNSA) Soars 5.8%: Is Further Upside Left in the Stock? (Zacks)
Mar-03-25 09:55AM	Wall Street Analysts See a 73.42% Upside in Kiniksa Pharmaceuticals (KNSA): Can the Stock Really Move This High? (Zacks) +5.82%
Mar-02-25 11:58AM	Is Kiniksa Pharmaceuticals International, plc (KNSA) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
08:45AM	Loading…
Feb-25-25 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
07:29AM	Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy (GlobeNewswire)
Feb-20-25 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 (GlobeNewswire)
Feb-10-25 10:32AM	Pharma Companies Turn to AI to Speed Up Drug Development, But Hit Hurdles (The Wall Street Journal)
Jan-13-25 07:30AM	Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance (GlobeNewswire) -8.83%
Jan-06-25 04:01PM	Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-26-24 04:01PM	Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-13-24 10:45AM	Is Kiniksa Pharmaceuticals (KNSA) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-12-24 04:01PM	Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference (GlobeNewswire)
04:25AM	Loading…
Oct-30-24 04:25AM	Q3 2024 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings Call Highlights: Impressive ... (GuruFocus.com)
Oct-29-24 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -15.68%
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-28-24 09:05AM	What To Expect From Kiniksa Pharmaceuticals International PLC (KNSA) Q3 2024 Earnings (GuruFocus.com)
08:00AM	Kiniksa Pharmaceuticals Partners with GRAMMY Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Oct-22-24 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 (GlobeNewswire)
Oct-09-24 09:55AM	Wall Street Analysts Think Kiniksa Pharmaceuticals (KNSA) Could Surge 42.34%: Read This Before Placing a Bet (Zacks)
Oct-08-24 09:10PM	Baker Bros. Advisors LP Increases Stake in Kiniksa Pharmaceuticals (GuruFocus.com)
Oct-01-24 08:00AM	NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted Campaign to Drive Awareness of Recurrent Pericarditis (GlobeNewswire)
Aug-28-24 04:01PM	Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-05-24 09:55AM	Wall Street Analysts Believe Kiniksa Pharmaceuticals (KNSA) Could Rally 30.11%: Here's is How to Trade (Zacks)
Jul-26-24 12:00PM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Is Up 0.09% in One Week: What You Should Know (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals (KNSA) is Your Friend, Here's Why (Zacks)
Jul-23-24 08:35AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +22.91%
07:30AM	Loading…
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-16-24 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024 (GlobeNewswire)
Jul-09-24 08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjogren's Disease (GlobeNewswire)
08:00AM	Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sj gren's Disease (GlobeNewswire)
Jun-24-24 08:00AM	Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis (GlobeNewswire)
Jun-17-24 08:30AM	Kiniksa Pharmaceuticals Sponsors American Heart Association's Addressing Recurrent Pericarditis Initiative (GlobeNewswire)
Jun-04-24 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-24 07:00AM	Sector Spotlight: Orphan Drug Developers With Significant Upside (News Direct)
May-07-24 04:01PM	Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
Apr-24-24 09:00AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-23-24 11:53AM	KNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:53AM	Kiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue Forecasts (GuruFocus.com)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:36AM	Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises (MT Newswires)
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Apr-16-24 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024 (GlobeNewswire)
Apr-02-24 07:30AM	Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart (GlobeNewswire)
Mar-01-24 09:55AM	Does Kiniksa Pharmaceuticals, Ltd. (KNSA) Have the Potential to Rally 32.45% as Wall Street Analysts Expect? (Zacks)
Feb-29-24 11:33PM	Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
12:00PM	Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice (Zacks)
09:21AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
08:40AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Q4 Earnings and Revenues Surpass Estimates (Zacks)
07:52AM	Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023 (GuruFocus.com)
07:30AM	Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Feb-21-24 04:01PM	Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Feb-12-24 09:55AM	Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know (Zacks)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jan-23-24 09:55AM	How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93% (Zacks)
08:50AM	Recent Price Trend in Kiniksa Pharmaceuticals, Ltd. (KNSA) is Your Friend, Here's Why (Zacks)
Jan-09-24 08:46AM	Is Kiniksa Pharmaceuticals (KNSA) Stock a Solid Choice Right Now? (Zacks)
Jan-04-24 07:30AM	Kiniksa Pharmaceuticals Provides Corporate Update (GlobeNewswire)
Jan-02-24 04:01PM	Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +5.64% +7.83%
Dec-23-23 09:00AM	Chief Accounting Officer Michael Megna Sells 9,316 Shares of Kiniksa Pharmaceuticals Ltd (KNSA) (GuruFocus.com)
Dec-15-23 02:30PM	The 3 Most Undervalued Biotech Stocks to Buy in December (InvestorPlace) +5.51%
Nov-24-23 02:05PM	Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How (Zacks)
Nov-20-23 09:55AM	Wall Street Analysts See a 70.27% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High? (Zacks)
Nov-09-23 10:01PM	7 Underappreciated Biotech Stocks to Pick Up on the Cheap (InvestorPlace) -5.83%
Nov-01-23 08:27AM	Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-31-23 10:48PM	Q3 2023 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents)
08:50AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Oct-24-23 04:01PM	Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023 (GlobeNewswire)
Oct-20-23 12:08PM	12 Cheap Biotech Stocks Smart Investors Are Piling Into (Insider Monkey)
Sep-29-23 12:43PM	25 Biggest Stocks with Negative Beta (Insider Monkey)
Aug-27-23 08:40AM	13 NASDAQ Stocks with Lowest PE Ratios That May Not Be Value Traps (Insider Monkey)
Aug-22-23 08:14AM	11 Most Undervalued Biotech Stocks to Buy According to Analysts (Insider Monkey)
Aug-18-23 09:04PM	HHLR ADVISORS, LTD. Increases Stake in Kiniksa Pharmaceuticals Ltd (GuruFocus.com)
Aug-10-23 10:33PM	Fairmount Funds Management LLC Acquires New Stake in Kiniksa Pharmaceuticals Ltd (GuruFocus.com)
Aug-07-23 06:14AM	Investing in Kiniksa Pharmaceuticals (NASDAQ:KNSA) a year ago would have delivered you a 41% gain (Simply Wall St.)
Jul-25-23 10:05PM	Q2 2023 Kiniksa Pharmaceuticals Ltd Earnings Call (Thomson Reuters StreetEvents) +30.39%
01:06PM	Why Shares of Kiniksa Pharmaceuticals Jumped Tuesday (Motley Fool)
08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
Jul-24-23 08:31AM	Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-18-23 04:01PM	Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 (GlobeNewswire)
Jul-17-23 08:00AM	Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023 (GlobeNewswire) +5.02%
Jul-04-23 08:24PM	3 Small-Cap Stocks That Are Worth the Gamble (InvestorPlace)
Jun-06-23 04:01PM	Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-03-23 06:14AM	Kiniksa Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.) +8.34%
May-02-23 08:45AM	Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.66%
07:30AM	Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution (GlobeNewswire)
May-01-23 04:01PM	Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023 (GlobeNewswire)
Apr-09-23 09:21AM	Could The Market Be Wrong About Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Given Its Attractive Financial Prospects? (Simply Wall St.)
Apr-05-23 01:40PM	7 Thrilling Biotech Stocks for Aggressive Investors to Buy (InvestorPlace)
Mar-31-23 09:35AM	After Plunging -13.29% in 4 Weeks, Here's Why the Trend Might Reverse for Kiniksa Pharmaceuticals, Ltd. (KNSA) (Zacks)
Mar-30-23 02:20PM	7 Small-Cap Stocks to Buy for Explosive Growth Potential (InvestorPlace)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 12:04PM	HCA Healthcare (HCA) Expands in Kansas With a Medical Plaza (Zacks)
Mar-23-23 02:25PM	7 Dirt-Cheap Stocks Sitting in the Sweet Spot (InvestorPlace)

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Megna Michael R	Officer	Mar 12 '25	Proposed Sale	22.45	9,051	203,207		Mar 12 04:47 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 10 '25	Option Exercise	3.80	7,000	26,600	88,975	Mar 12 04:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Mar 10 '25	Sale	21.06	12,409	261,334	76,566	Mar 12 04:37 PM
Ragosa Mark	Officer	Mar 12 '25	Proposed Sale	22.25	36,372	809,405		Mar 12 04:04 PM
Tessari Eben	Officer	Mar 10 '25	Proposed Sale	21.06	12,409	261,330		Mar 10 05:13 PM
Tessari Eben	CHIEF OPERATING OFFICER	Feb 10 '25	Option Exercise	3.80	7,000	26,600	95,975	Feb 12 04:57 PM
Tessari Eben	CHIEF OPERATING OFFICER	Feb 10 '25	Sale	19.57	14,000	273,980	81,975	Feb 12 04:57 PM
Tessari Eben	Officer	Feb 10 '25	Proposed Sale	19.57	14,000	274,041		Feb 10 05:37 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jan 13 '25	Option Exercise	3.80	7,000	26,600	102,975	Jan 15 04:42 PM
Tessari Eben	CHIEF OPERATING OFFICER	Jan 13 '25	Sale	18.24	14,000	255,413	88,975	Jan 15 04:42 PM
Tessari Eben	Officer	Jan 13 '25	Proposed Sale	18.24	14,000	255,390		Jan 13 05:27 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 16 '24	Option Exercise	1.59	16,017	25,467	118,992	Dec 18 04:45 PM
Tessari Eben	CHIEF OPERATING OFFICER	Dec 16 '24	Sale	20.44	23,017	470,467	95,975	Dec 18 04:45 PM
Tessari Eben	Officer	Dec 16 '24	Proposed Sale	20.44	23,017	470,373		Dec 16 05:17 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 09 '24	Option Exercise	11.10	18,860	209,346	41,818	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 06 '24	Option Exercise	10.76	2,406	25,889	25,364	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 09 '24	Sale	21.38	18,860	403,227	22,958	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 06 '24	Sale	21.27	8,969	190,771	22,958	Dec 10 04:34 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 03 '24	Option Exercise	10.76	8,969	96,506	31,927	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 04 '24	Option Exercise	10.76	5,024	54,058	27,982	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 05 '24	Option Exercise	10.76	1,123	12,083	24,081	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 03 '24	Sale	21.45	8,969	192,385	22,958	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 04 '24	Sale	21.25	5,024	106,760	22,958	Dec 05 07:14 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Dec 05 '24	Sale	21.25	1,123	23,864	22,958	Dec 05 07:14 PM
Ragosa Mark	Officer	Dec 03 '24	Proposed Sale	21.25	72,754	1,546,022		Dec 03 05:25 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 27 '24	Option Exercise	11.10	8,637	95,871	35,165	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 29 '24	Option Exercise	11.10	9	100	26,537	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 27 '24	Sale	22.45	8,637	193,901	26,528	Dec 02 04:36 PM
Megna Michael R	CHIEF ACCOUNTING OFFICER	Nov 29 '24	Sale	22.45	9	202	26,528	Dec 02 04:36 PM
Megna Michael R	Officer	Nov 27 '24	Proposed Sale	22.45	17,697	397,298		Nov 27 05:13 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 18 '24	Option Exercise	1.59	10,000	15,900	119,975	Nov 20 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Nov 18 '24	Sale	21.04	17,000	357,680	102,975	Nov 20 04:39 PM
Tessari Eben	Officer	Nov 18 '24	Proposed Sale	21.04	17,000	357,641		Nov 18 05:50 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 06 '24	Option Exercise	1.59	89,561	142,402	169,112	Nov 08 04:34 PM
Patel Sanj K	CHAIRMAN & CEO	Nov 06 '24	Sale	23.00	89,561	2,059,903	79,551	Nov 08 04:34 PM
Patel Sanj K	Officer	Nov 06 '24	Proposed Sale	23.00	89,561	2,060,253		Nov 06 04:11 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 15 '24	Option Exercise	1.59	10,000	15,900	126,975	Oct 17 04:35 PM
Tessari Eben	CHIEF OPERATING OFFICER	Oct 15 '24	Sale	26.87	17,000	456,790	109,975	Oct 17 04:35 PM
Tessari Eben	Officer	Oct 15 '24	Proposed Sale	26.87	17,000	456,789		Oct 15 04:57 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 23 '24	Option Exercise	1.59	10,000	15,900	134,475	Sep 25 04:39 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 23 '24	Sale	24.99	17,500	437,325	116,975	Sep 25 04:39 PM
Tessari Eben	Officer	Sep 23 '24	Proposed Sale	24.99	17,500	437,258		Sep 23 05:02 PM
Tessari Eben	CHIEF OPERATING OFFICER	Sep 02 '24	Option Exercise	0.00	1,964	0	125,052	Sep 04 08:53 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	1.88	60,692	113,809	112,730	Sep 04 08:52 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	26.12	60,692	1,584,991	52,038	Sep 04 08:52 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Sep 03 '24	Option Exercise	10.95	68,506	750,192	90,242	Sep 04 08:42 PM
Moat Ross	CHIEF COMMERCIAL OFFICER	Sep 03 '24	Sale	26.12	68,506	1,789,190	21,736	Sep 04 08:42 PM
Moat Ross	Officer	Sep 03 '24	Proposed Sale	26.12	68,506	1,789,288		Sep 03 05:17 PM
Paolini John F.	Officer	Sep 03 '24	Proposed Sale	26.12	90,217	2,356,351		Sep 03 05:16 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 27 '24	Option Exercise	1.59	10,000	15,900	137,411	Aug 29 04:36 PM
Tessari Eben	CHIEF OPERATING OFFICER	Aug 27 '24	Sale	26.91	17,500	470,925	119,911	Aug 29 04:36 PM
Tessari Eben	Officer	Aug 27 '24	Proposed Sale	26.91	17,500	470,904		Aug 27 05:17 PM
Patel Sanj K	CHAIRMAN & CEO	Jul 23 '24	Option Exercise	1.59	136,124	216,437	199,136	Jul 25 04:33 PM
Patel Sanj K	CHAIRMAN & CEO	Jul 23 '24	Sale	25.65	136,124	3,491,947	63,012	Jul 25 04:33 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jul 23 '24	Option Exercise	11.10	24,248	269,153	43,501	Jul 25 04:32 PM
Ragosa Mark	CHIEF FINANCIAL OFFICER	Jul 23 '24	Sale	24.79	24,248	601,108	19,253	Jul 25 04:32 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Jul 23 '24	Option Exercise	1.86	22,000	40,920	69,803	Jul 25 04:31 PM
Paolini John F.	CHIEF MEDICAL OFFICER	Jul 23 '24	Sale	26.32	22,000	578,966	47,803	Jul 25 04:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Kiniksa Pharmaceuticals International Plc

Upgrade your FINVIZ experience